DK3209317T3 - Terlipressin til behandling af hepatorenalt syndrom type 1 - Google Patents

Terlipressin til behandling af hepatorenalt syndrom type 1 Download PDF

Info

Publication number
DK3209317T3
DK3209317T3 DK15791430.0T DK15791430T DK3209317T3 DK 3209317 T3 DK3209317 T3 DK 3209317T3 DK 15791430 T DK15791430 T DK 15791430T DK 3209317 T3 DK3209317 T3 DK 3209317T3
Authority
DK
Denmark
Prior art keywords
terlipressine
treatment
syndrome type
hepatorenal syndrome
hepatorenal
Prior art date
Application number
DK15791430.0T
Other languages
Danish (da)
English (en)
Inventor
Stephen Chris Pappas
Jim Potenziano
Khurram Jamil
Original Assignee
Mallinckrodt Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Pharmaceuticals Ireland Ltd filed Critical Mallinckrodt Pharmaceuticals Ireland Ltd
Application granted granted Critical
Publication of DK3209317T3 publication Critical patent/DK3209317T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024Measuring pulse rate or heart rate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002Implant devices for drainage of body fluids from one part of the body to another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/4925Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N2015/1024Counting particles by non-optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
DK15791430.0T 2014-10-24 2015-10-22 Terlipressin til behandling af hepatorenalt syndrom type 1 DK3209317T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US201562151384P 2015-04-22 2015-04-22
PCT/US2015/056861 WO2016065117A1 (en) 2014-10-24 2015-10-22 Method of treating patients with hepatorenal syndrome type 1

Publications (1)

Publication Number Publication Date
DK3209317T3 true DK3209317T3 (da) 2022-02-07

Family

ID=54478246

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15791430.0T DK3209317T3 (da) 2014-10-24 2015-10-22 Terlipressin til behandling af hepatorenalt syndrom type 1
DK21205752.5T DK3978074T3 (da) 2014-10-24 2015-10-22 Terlipressin til behandling af hepatorenalt syndrom type 1

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21205752.5T DK3978074T3 (da) 2014-10-24 2015-10-22 Terlipressin til behandling af hepatorenalt syndrom type 1

Country Status (15)

Country Link
US (2) US10335452B2 (enExample)
EP (3) EP3981420A1 (enExample)
JP (4) JP6673915B2 (enExample)
CN (2) CN107206049B (enExample)
AU (1) AU2015335855A1 (enExample)
CA (1) CA2965325A1 (enExample)
DK (2) DK3209317T3 (enExample)
ES (2) ES2904492T3 (enExample)
FI (1) FI3978074T3 (enExample)
HR (1) HRP20220225T1 (enExample)
HU (1) HUE058066T2 (enExample)
PL (2) PL3209317T3 (enExample)
PT (2) PT3978074T (enExample)
SI (1) SI3209317T1 (enExample)
WO (1) WO2016065117A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
JP6673915B2 (ja) * 2014-10-24 2020-03-25 マリンクロット ホスピタル プロダクツ アイピー リミテッド 1型肝腎症候群患者の治療方法
EP3528828B1 (en) * 2016-10-21 2025-01-29 Amryt Endo, Inc. Terlipressin composition for use in treating ascites
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110251469B (zh) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 一种醋酸特利加压素制剂及其制备方法
WO2021084483A1 (en) * 2019-10-30 2021-05-06 Mallinckrodt Hospital Products IP Unlimited Company Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
US20080221551A1 (en) * 2007-03-09 2008-09-11 Flowmedica, Inc. Acute kidney injury treatment systems and methods
US9050286B2 (en) 2007-08-14 2015-06-09 Ferring B.V. Use of peptidic vasopression receptor agonists
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2661310T3 (es) 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
AU2011279144A1 (en) * 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
CN103254295A (zh) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 特利加压素的制备方法
JP6673915B2 (ja) * 2014-10-24 2020-03-25 マリンクロット ホスピタル プロダクツ アイピー リミテッド 1型肝腎症候群患者の治療方法
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス,インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
JP6989571B2 (ja) 2022-01-05
JP2021155433A (ja) 2021-10-07
US20190328831A1 (en) 2019-10-31
EP3209317B1 (en) 2021-12-08
US20160113994A1 (en) 2016-04-28
CN114028536B (zh) 2024-07-09
SI3209317T1 (sl) 2022-05-31
US10335452B2 (en) 2019-07-02
ES2904492T3 (es) 2022-04-05
CA2965325A1 (en) 2016-04-28
JP2017534618A (ja) 2017-11-24
JP2022171795A (ja) 2022-11-11
CN107206049A (zh) 2017-09-26
JP7346494B2 (ja) 2023-09-19
AU2015335855A1 (en) 2017-05-18
FI3978074T3 (fi) 2024-05-20
CN114028536A (zh) 2022-02-11
CN107206049B (zh) 2021-12-07
JP2019199485A (ja) 2019-11-21
WO2016065117A1 (en) 2016-04-28
EP3209317A1 (en) 2017-08-30
DK3978074T3 (da) 2024-05-13
EP3981420A1 (en) 2022-04-13
EP3978074B1 (en) 2024-03-06
HUE058066T2 (hu) 2022-06-28
HRP20220225T1 (hr) 2022-04-29
JP6673915B2 (ja) 2020-03-25
EP3978074A1 (en) 2022-04-06
PL3209317T3 (pl) 2022-05-23
ES2987577T3 (es) 2024-11-15
PT3209317T (pt) 2022-01-19
PL3978074T3 (pl) 2024-08-12
PT3978074T (pt) 2024-05-13

Similar Documents

Publication Publication Date Title
EP3564866A4 (en) CALCULATION PROCESS
DK3805376T3 (da) Modificeret virus
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
EP3393508C0 (en) Zika virus purification
EP3458756A4 (en) FLANGE ADAPTER
DK3209317T3 (da) Terlipressin til behandling af hepatorenalt syndrom type 1
BR112017019682A2 (pt) fluoropolímeros modificados
IL247857B (en) Dynamic enablement of multithreading
DE112016004797T8 (de) Zentrifugalkompressor
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
DK3666258T3 (da) Fremgangsmåde til behandling af prader-willis syndrom
HUE042606T2 (hu) Eljárás apolipoprotein kimutatására
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3463001T3 (da) Kogegrej
DK3188727T3 (da) Tasimelteon til behandling af smith-magenis¿ syndrom
KR20180085035A (ko) 세탁기
DK3551355T3 (da) Immobiliseret indsats
EP3498837A4 (en) Genome editing method
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
DK3484475T3 (da) 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
EP3439523A4 (en) UTENSIL
DK3184823T3 (da) Centrifugalpumpe
DE112016005703A5 (de) Stufenlosgetriebe
EP3417011A4 (en) Polyimides
ITUA20162057A1 (it) Natante